Home › SEC Filings › Press Releases
Press Releases
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| LBRX | PRESS-RELEASE | neutral | 5/10 | LB Pharmaceuticals announced the initiation of its pivotal Phase 3 NOVA-2 trial evaluating LB-102, a novel benzamide ant | Mar 25, 2026 |
| RXRX | PRESS-RELEASE | neutral | 3/10 | Recursion Pharmaceuticals announced the appointment of Dr. Vicki Goodman as its new Chief Medical Officer, effective Apr | Mar 25, 2026 |
| AVXL | PRESS-RELEASE | bearish | 8/10 | Anavex Life Sciences has withdrawn its EU marketing application for blarcamesine as an add-on therapy for early Alzheime | Mar 25, 2026 |
| MAZE | PRESS-RELEASE | bullish | 8/10 | Maze Therapeutics reported positive Phase 2 HORIZON trial data for MZE829 in APOL1-mediated kidney disease (AMKD), showi | Mar 25, 2026 |
| CCCC | PRESS-RELEASE | neutral | 5/10 | C4 Therapeutics has dosed the first patient in a Phase 1b trial combining its investigational drug cemsidomide with Pfiz | Mar 25, 2026 |
| BEAM | PRESS-RELEASE | bullish | 8/10 | Beam Therapeutics announced updated Phase 1/2 data for BEAM-302, a base-edited therapy for alpha-1 antitrypsin deficienc | Mar 25, 2026 |
| TERN | PRESS-RELEASE | bullish | 9/10 | Merck will acquire Terns Pharmaceuticals for $53.00 per share in cash, representing a total equity value of $6.7 billion | Mar 25, 2026 |
| APGE | PRESS-RELEASE | bearish | 6/10 | Apogee Therapeutics priced an underwritten public offering of 5,000,000 shares at $70.00 per share, raising approximatel | Mar 24, 2026 |
| XRTX | PRESS-RELEASE | neutral | 5/10 | XORTX Therapeutics announced shareholder approval for a reverse stock split of up to 5:1 to comply with NASDAQ's $1.00 m | Mar 24, 2026 |
| PDSB | PRESS-RELEASE | neutral | 3/10 | PDS Biotechnology announced it will report its Q4 and full-year 2025 financial results and provide a clinical update on | Mar 24, 2026 |
| ABSI | PRESS-RELEASE | neutral | 4/10 | Absci Corporation announced the successful dosing of the first three cohorts in the SAD portion of its ABS-201™ HEADLINE | Mar 24, 2026 |
| BMEA | PRESS-RELEASE | neutral | 3/10 | Biomea Fusion, Inc. (BMEA) reported its full-year 2025 financial results and provided a business update. As a clinical-s | Mar 24, 2026 |
| LODE | PRESS-RELEASE | neutral | 3/10 | Analysis based on filing metadata only, document content was unavailable | Mar 24, 2026 |
| MXCT | PRESS-RELEASE | bearish | 7/10 | MaxCyte reported Q4 and full-year 2025 results with total revenue of $7.3M and $33.0M, respectively, representing 16% an | Mar 24, 2026 |
| BCDA | PRESS-RELEASE | bearish | 6/10 | BioCardia reported its 2025 financial results, showing no revenue and a net loss of $8.2 million, with cash of $2.5 mill | Mar 24, 2026 |
| SLXN | PRESS-RELEASE | bullish | 8/10 | Silexion Therapeutics has received approval from the Israeli Ministry of Health to initiate a Phase 2/3 clinical trial f | Mar 24, 2026 |
| BIOA | PRESS-RELEASE | mixed | 6/10 | BioAge Labs reported its full-year 2025 financial results alongside key clinical and corporate updates, including positi | Mar 24, 2026 |
| PPCB | PRESS-RELEASE | neutral | 4/10 | Propanc Biopharma announced a new multi-year research collaboration with the Universities of Jaén and Granada in Spain t | Mar 24, 2026 |
| SLXN | PRESS-RELEASE | bullish | 8/10 | Silexion Therapeutics received formal approval from the Israeli Ministry of Health to initiate a Phase 2/3 clinical tria | Mar 24, 2026 |
| ENLV | PRESS-RELEASE | mixed | 6/10 | Enlivex announced a $21 million convertible debt financing, a $10 million token purchase at a discount, an extension of | Mar 24, 2026 |
| LENZ | PRESS-RELEASE | mixed | 6/10 | LENZ Therapeutics reported its first commercial revenue from VIZZ, generating $1.6 million in net product sales in Q4 20 | Mar 24, 2026 |
| IMNN | PRESS-RELEASE | neutral | 3/10 | Imunon, Inc. announced it will host a conference call on March 31, 2026, to discuss its 2025 financial results and provi | Mar 24, 2026 |
| LXRX | PRESS-RELEASE | mixed | 6/10 | Lexicon Pharmaceuticals presented new clinical data for sotagliflozin at the American College of Cardiology Annual Meeti | Mar 24, 2026 |
| OCGN | PRESS-RELEASE | bullish | 8/10 | Ocugen announced positive 12-month Phase 2 data for OCU410, its gene therapy for geographic atrophy (GA) secondary to dr | Mar 24, 2026 |
| PVLA | PRESS-RELEASE | neutral | 3/10 | Palvella Therapeutics announced it will report its full year 2025 financial results on March 31, 2026, followed by a con | Mar 24, 2026 |
| ACHV | PRESS-RELEASE | mixed | 6/10 | Achieve Life Sciences reported Q4 and full-year 2025 financial results, highlighted by a net loss of $14.7M for the quar | Mar 24, 2026 |
| ELAB | PRESS-RELEASE | neutral | 4/10 | PMGC Holdings Inc. announced that its subsidiary, Silicon Valley Manufacturing (SVM), has completed ITAR registration, e | Mar 24, 2026 |
| FENC | PRESS-RELEASE | bullish | 8/10 | Fennec Pharmaceuticals reported strong financial and operational performance for FY 2025, with record net product sales | Mar 24, 2026 |
| BNTX | PRESS-RELEASE | bullish | 8/10 | BioNTech presented new clinical data from its late-stage lung cancer programs at the European Lung Cancer Congress 2026, | Mar 24, 2026 |
| ATAI | PRESS-RELEASE | neutral | 5/10 | AtaiBeckley Inc. (ATAI) was added to the S&P Total Market Index, S&P Completion Index, and CRSP U.S. benchmark indices e | Mar 24, 2026 |